SciELO - Scientific Electronic Library Online

vol.38 número2Fiebre Q: revisión histórica de casos humanos en Uruguay. Abordaje desde la complementariedad entre las ciencias médicas y veterinariasFibromatosis mesentérica solitaria. Reporte de caso y revisión de la literatura índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados



Links relacionados


Revista Médica del Uruguay

versión impresa ISSN 0303-3295versión On-line ISSN 1688-0390


DUARTE, Victoria; TABORDA, Ana; DE LEON, Yesika  y  FACAL, Jorge. Methylprednisolone-induced hepatotoxicity. A case report. Rev. Méd. Urug. [online]. 2022, vol.38, n.2, e701.  Epub 01-Jun-2022. ISSN 0303-3295.


drug induced hepatotoxicity and toxicity induced by other agents is a frequent form of liver injury, accounting for larger number of cases than viral hepatitis in some countries. Presentation may be variable, from an isolated alteration in the liver function test to severe forms of acute fulminant liver failure. The study presents a case of severe liver injury following a short cycle with high doses of intravenous methylprednisolone.

Clinical case:

45 year-old female patient. Personal history of multiple sclerosis, with relapse 40 days prior to the consultation, treated with intravenous methylprednisolone. The patient consulted for jaundice with one week of evolution, abdominal pain, vomiting, anorexia, asthenia, and adynamia in the last month. Paraclinical tests find mixed hyperbilirubinemia, increased transaminases and decreased prothrombin time (PT). Viral, autoimmune and metabolic etiology are ruled out and a hypothesis is made for methylprednisolone-induced hepatotoxicity. The latter is confirmed and evolution is favorable, liver enzymogram being normal after three months, the same as the prothrombin time upon the interruption of methylprednisolone therapy.


the first step to diagnose hepatotoxicity is excluding other causes of liver injury.

Next, the temporal relationship between drug exposure and liver injury needs to be demonstrated. Last, withdrawing the drug is usually accompanied by clinical and tests improvement. A high degree of suspicion is necessary to diagnose this condition. Therapies with high doses of methylprednisolone may cause severe hepatitis, and it is recurrent upon re-exposure to the drug. Patients with autoimmune diseases have greater risks of developing hepatotoxicity, what results in a therapeutic challenge.

Palabras clave : Hepatotoxicity; Metilprednisolona; Multiple sclerosis.

        · resumen en Español | Portugués     · texto en Español     · Español ( pdf )